Cargando…

Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate

Hyperkalaemia is a life-threatening condition, resulting from decreased renal function or dysfunctional homoeostatic mechanisms, often affecting patients with cardiovascular (CV) disease. Drugs such as renin-angiotensin-aldosterone system inhibitors (RAASi) are known to improve outcomes in CV patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosano, Giuseppe M C, Spoletini, Ilaria, Agewall, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392412/
https://www.ncbi.nlm.nih.gov/pubmed/30837802
http://dx.doi.org/10.1093/eurheartj/suy035
_version_ 1783398476725354496
author Rosano, Giuseppe M C
Spoletini, Ilaria
Agewall, Stefan
author_facet Rosano, Giuseppe M C
Spoletini, Ilaria
Agewall, Stefan
author_sort Rosano, Giuseppe M C
collection PubMed
description Hyperkalaemia is a life-threatening condition, resulting from decreased renal function or dysfunctional homoeostatic mechanisms, often affecting patients with cardiovascular (CV) disease. Drugs such as renin-angiotensin-aldosterone system inhibitors (RAASi) are known to improve outcomes in CV patients but can also cause drug-induced hyperkalaemia. New therapeutic options exist to enhance potassium excretion in these patients. To this aim, we reviewed pharmacological properties and available data on patiromer and sodium zirconium cyclosilicate for the treatment of hyperkalaemia. These agents have been shown in randomized trials to significantly reduce serum potassium in patients with hyperkalaemia on renin-angiotensin-aldosterone system inhibitors. Additional research should focus on their long-term effects/safety profiles and drug–drug interactions.
format Online
Article
Text
id pubmed-6392412
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-63924122019-03-05 Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate Rosano, Giuseppe M C Spoletini, Ilaria Agewall, Stefan Eur Heart J Suppl Articles Hyperkalaemia is a life-threatening condition, resulting from decreased renal function or dysfunctional homoeostatic mechanisms, often affecting patients with cardiovascular (CV) disease. Drugs such as renin-angiotensin-aldosterone system inhibitors (RAASi) are known to improve outcomes in CV patients but can also cause drug-induced hyperkalaemia. New therapeutic options exist to enhance potassium excretion in these patients. To this aim, we reviewed pharmacological properties and available data on patiromer and sodium zirconium cyclosilicate for the treatment of hyperkalaemia. These agents have been shown in randomized trials to significantly reduce serum potassium in patients with hyperkalaemia on renin-angiotensin-aldosterone system inhibitors. Additional research should focus on their long-term effects/safety profiles and drug–drug interactions. Oxford University Press 2019-02 2019-02-26 /pmc/articles/PMC6392412/ /pubmed/30837802 http://dx.doi.org/10.1093/eurheartj/suy035 Text en Published on behalf of the European Society of Cardiology. © The Author(s) 2019. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Articles
Rosano, Giuseppe M C
Spoletini, Ilaria
Agewall, Stefan
Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
title Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
title_full Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
title_fullStr Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
title_full_unstemmed Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
title_short Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
title_sort pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392412/
https://www.ncbi.nlm.nih.gov/pubmed/30837802
http://dx.doi.org/10.1093/eurheartj/suy035
work_keys_str_mv AT rosanogiuseppemc pharmacologyofnewtreatmentsforhyperkalaemiapatiromerandsodiumzirconiumcyclosilicate
AT spoletiniilaria pharmacologyofnewtreatmentsforhyperkalaemiapatiromerandsodiumzirconiumcyclosilicate
AT agewallstefan pharmacologyofnewtreatmentsforhyperkalaemiapatiromerandsodiumzirconiumcyclosilicate